CBLL — CeriBell, Inc. stock price, charts and financials

QT65CeriBell, Inc.

CeriBell, Inc. (NASDAQ: CBLL) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
24.37
-0.63-2.52%
OverviewShort InterestFilings
CBLLQT65CeriBell, Inc.·NASDAQ
24.37-2.52%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BVS+2.22%$12.91BBNX+2.15%$21.89INMD-1.31%$14.35ENOV+1.35%$18.04IRMD-0.75%$82.12SIBN+0.28%$18.09AVR-3.09%$8.16VREX-0.27%$18.49
Snapshot
Index-P/E-EPS (ttm)-1.76Insider Own23.32%Shs Outstand37.94MPerf Week3.13%
Market Cap924.66MForward P/E-EPS next Y-1.61Insider Trans-6.21%Shs Float24.72MPerf Month-2.09%
Enterprise Value817.66MPEG-EPS next Q-0.50Inst Own-Short Float7.71%Perf Quarter35.16%
Income-66.00MP/S9.07EPS this Y-12.09%Inst Trans-Short Ratio4.96Perf Half Y28.06%
Sales102.00MP/B7.22EPS next Y18.49%ROA-39.67%Short Interest1.91MPerf YTD11.13%
Book/sh3.37P/C7.17EPS next 5Y-ROE-44.85%52W High25.63 -4.92%Perf Year103.93%
Cash/sh3.40P/FCF-EPS past 3/5Y-ROIC-46.54%52W Low10.85 124.61%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y50.71% -Gross Margin88.90%Volatility4.25% 3.45%Perf 5Y-
Dividend TTM-EV/Sales8.02EPS Y/Y TTM-55.75%Oper. Margin-68.62%ATR (14)0.93Perf 10Y-
Dividend Ex-Date-Quick Ratio8.79Sales Y/Y TTM56.92%Profit Margin-64.73%RSI (14)57.11Recom2.00
Dividend Gr. 3/5Y-Current Ratio9.18EPS Q/Q-34.21%SMA200.64%Beta1.20Target Price27.50
Payout0.00%Debt/Eq0.14Sales Q/Q33.33%SMA5013.32%Rel Volume2.32Prev Close25.00
Employees327LT Debt/Eq0.14EarningsNov 03SMA20020.91%Avg Volume400.34KPrice24.37
IPO DateOct 11, 2024Option/ShortYes / YesEPS/Sales Surpr.-8.24% 3.01%Net Debt/EBITDA0.17Volume928,319Change-2.52%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-03-26ReiteratedRaymond James$29
Aug-11-26ReiteratedCanaccord GenuityBuy$25 → $26
May-12-26ReiteratedCanaccord GenuityBuy$30 → $25
Dec-15-25ReiteratedBTIGBuy$30
Nov-05-24ReiteratedCanaccord Genuity$30
Latest News· Times ET
Sep-11-26
Sep-11-2602:59AM
BTIG Reiterates Buy on CeriBell, Maintains $30 Price TargetBenzinga
Sep-01-26
Sep-01-2611:52PM
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLLdefenseworld.net
Aug-26-26
Aug-26-2611:39PM
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLLdefenseworld.net
Aug-18-26
Aug-18-2604:26AM
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga
Aug-12-26
Aug-12-2607:05AM
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Pushmarketbeat.com
Aug-11-26
Aug-11-2607:46AM
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26Benzinga
01:28AM
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-10-26
Aug-10-2604:00PM
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earningszacks.com
02:56PM
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimateszacks.com
02:04PM
CeriBell Q2 Earnings Call Highlightsmarketbeat.com
03:00AM
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Reviewglobenewswire.com
Aug-03-26
Aug-03-2603:23AM
CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor SystemBenzinga
03:00AM
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor Systemglobenewswire.com
Jul-29-26
Jul-29-2603:00AM
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefeglobenewswire.com
Jul-28-26
Jul-28-2612:05PM
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conferenceglobenewswire.com
Company

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue1028965——
Cost of Goods Sold Incl. D&A11119——
Gross Profit917857——
Selling, General and Administrative Excl. Other13811883——
Research and Development231914——
Other Operating Expense00-1——
Operating Income-71-58-40——
Interest Expense022——
Unusual Expense
—————
Non-Operating Income (Expense)671——
Net Income Before Taxes-66-53-40——
Income Taxes
000——
Consolidated Net Income-66-53-40——
Net Income From Continuing Operations-66-53-40——
Net Income-66-53-40——
EPS (Recurring)-1.76-1.46-1.13——
EPS (Basic, Before Extraordinaries)-1.76-1.46-1.13——
EPS (Diluted)-1.76-1.46-1.13——
EBITDA-64-50-37——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio9.089.1214.33——
Gross Margin89.2287.6487.69——
Operating Margin-69.61-65.17-61.54——
Net Margin-64.71-59.55-61.54——
Shares Outstanding383736——
Market Capitalization926811932——
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$27.16$22.57$17.98$13.39$8.80● Close Price0.00M1.16M2.32M3.49M4.65MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Chao XingjuanPresident and CEOSep 15 '26Sale25.0320,846521,775746,345Sep 17
Blumberg ScottChief Financial OfficerSep 15 '26Option Exercise9.418467,961147,446Sep 17
Blumberg ScottChief Financial OfficerSep 15 '26Sale25.0084621,150146,600Sep 17
Foehr DavidSenior VP, Finance and PAOSep 08 '26Sale24.259,255224,45134,144Sep 10
Woo RaymondChief Technology OfficerSep 08 '26Option Exercise2.7613,27636,653208,005Sep 10
Woo RaymondChief Technology OfficerSep 08 '26Sale24.334,887118,901203,118Sep 10
Foehr DavidSenior VP, Finance and PAOSep 08 '26Option Exercise4.707,50035,25041,644Sep 10
Blumberg ScottChief Financial OfficerSep 02 '26Sale25.0065216,300146,600Sep 04
Chao XingjuanPresident and CEOSep 02 '26Option Exercise4.7025,000117,500806,731Sep 04
Chao XingjuanPresident and CEOSep 02 '26Sale24.6139,540973,079767,191Sep 04
Blumberg ScottChief Financial OfficerSep 02 '26Option Exercise9.416526,135147,252Sep 04
Foehr DavidSenior VP, Finance and PAOAug 24 '26Sale23.9585920,57335,899Aug 25
Foehr DavidSenior VP, Finance and PAOAug 21 '26Sale24.0299323,85236,758Aug 25
Manni Joseph S.Chief Revenue OfficerAug 21 '26Sale24.021,36132,69155,956Aug 25
Woo RaymondChief Technology OfficerAug 21 '26Sale24.021,97947,536194,729Aug 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.